GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Cyclically Adjusted PB Ratio

Hepion Pharmaceuticals (FRA:336) Cyclically Adjusted PB Ratio : (As of May. 23, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Hepion Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Hepion Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Hepion Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hepion Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hepion Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Hepion Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hepion Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Hepion Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Hepion Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Hepion Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.335/129.4194*129.4194
=1.335

Current CPI (Dec. 2023) = 129.4194.

Hepion Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 -3,216.970 99.695 -4,176.141
201406 -1,308.485 100.560 -1,684.011
201409 211.616 100.428 272.706
201412 -854.271 99.070 -1,115.974
201503 -2,700.503 99.621 -3,508.268
201506 -4,594.472 100.684 -5,905.749
201509 -6,743.719 100.392 -8,693.645
201512 -3,279.508 99.792 -4,253.149
201603 -4,565.574 100.470 -5,881.074
201606 -3,826.389 101.688 -4,869.881
201609 -866.935 101.861 -1,101.483
201612 786.607 101.863 999.406
201703 -234.095 102.862 -294.534
201706 1,055.621 103.349 1,321.906
201709 475.072 104.136 590.418
201712 0.000 104.011 0.000
201803 215.303 105.290 264.645
201806 -180.236 106.317 -219.401
201809 262.747 106.507 319.272
201812 13.997 105.998 17.090
201903 -66.667 107.251 -80.447
201906 83.565 108.070 100.074
201909 76.293 108.329 91.146
201912 66.539 108.420 79.427
202003 50.808 108.902 60.381
202006 32.616 108.767 38.809
202009 20.999 109.815 24.748
202012 19.922 109.897 23.461
202103 25.537 111.754 29.574
202106 23.740 114.631 26.803
202109 22.511 115.734 25.173
202112 21.199 117.630 23.324
202203 20.235 121.301 21.589
202206 16.288 125.017 16.862
202209 15.254 125.227 15.765
202212 11.928 125.222 12.328
202303 8.689 127.348 8.830
202306 5.934 128.729 5.966
202309 3.531 129.860 3.519
202312 1.335 129.419 1.335

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hepion Pharmaceuticals  (FRA:336) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Hepion Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (FRA:336) Business Description

Traded in Other Exchanges
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines